Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$1,204.91 USD

1,204.91
83,979

+3.15 (0.26%)

Updated Aug 28, 2024 01:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Ekta Bagri headshot

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.

Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma

REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

HRMY or REGN: Which Is the Better Value Stock Right Now?

HRMY vs. REGN: Which Stock Is the Better Value Option?

Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition

Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.

Ekta Bagri headshot

Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News

Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug

Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

HRMY vs. REGN: Which Stock Is the Better Value Option?

HRMY vs. REGN: Which Stock Is the Better Value Option?

Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates

Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales

Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.

Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent

Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP

Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues

Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.

Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up

Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.

Ethan Feller headshot

Defensive Sectors Breakout: 3 Stocks to Buy Now for Protection

AvalonBay Communities, Regeneron Pharmaceuticals and Public Service Enterprise Group are all rallying as investors rotate into defensive sectors

Compared to Estimates, Regeneron (REGN) Q2 Earnings: A Look at Key Metrics

The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales

Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.

Regeneron (REGN) Surpasses Q2 Earnings and Revenue Estimates

Regeneron (REGN) delivered earnings and revenue surprises of 9.37% and 4.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Ekta Bagri headshot

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.

Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Regeneron and Optex Systems

Goldman Sachs, RTX, Regeneron and Optex Systems are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Goldman Sachs, RTX & Regeneron

Today's Research Daily features new research reports on 16 major stocks, including The Goldman Sachs Group, Inc. (GS), RTX Corporation (RTX) and Regeneron Pharmaceuticals, Inc. (REGN), as well as a micro-cap stock Optex Systems Holdings, Inc (OPXS).

Countdown to Regeneron (REGN) Q2 Earnings: Wall Street Forecasts for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.